Clinical andor biochemical response may diminish to some extent during prolonged therapy. Sandostatin is not compatible in total parenteral nutrition. Octreotide may be administered directly by subcutaneous s. For solution and drug compatibility information, see compatibility under stability. Sandostatin octreotide acetate injection, a cyclic octapeptide prepared. Octreotide lar pharmacokinetics is similar once the drug is released from microspheres. Incompatibilities are based on meeting any of the following criteria. Reconstituted octreotide lar suspension must never be given iv. Therefore, no compatibility data with other products have. Australian injectable drugs handbook 7th edition june 2018 update 363. Furthermore, zero of the studies cited use the concentration of octreotide in question.
A legend at the bottom of the page lists all compatibility types, and hovering your mouse over the icon will open a popup with the full. Standard dilution amount of drug infusion volume infusion rate. Allow solution to come to room temperature before administration if possible. Sandostatin, sandostatin lar octreotide dosing, indications. Trissel, fashp, 2010, american society of healthsystem pharmacists. They were all dextrose 5% in water d5w, despite octreotide being compatible in ns in concentrations ranging from 1.
Octreotide acetate pharmacokinetics absorption bioavailability. Octreotide acetate is commercially available as an immediaterelease shortacting injection for subq or iv administration and as a longacting extendedrelease suspension for im administration. Sandostatin octreotide acetate may be administered subcutaneously or intravenously. Initially 20 mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30 mg every 4 weeks, to be administered into the gluteal muscle, for acromegaly, start depot 1 day after the last dose of subcutaneous octreotide, for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks. Stable in sterile isotonic saline solutions or dextrose 5% in water d5w for 24 hours. Print off separate octreotide infusion sheet for charting and dosing rates. Additive compatibility drugs in syringe compatibility. Sandostatin octreotide acetate is stable in sterile isotonic saline solutions or sterile solutions of dextrose 5% in water for 24 hours. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose.
The iv drug compatibility chart is based on information from the handbook of injectable drugs, 16th edition, by lawrence a. Because you can access epocrates intelligence instantly, your attention stays where it belongs. Trissels 2 clinical pharmaceutics database parenteral compatibility. Emergency surgery in somatostatin analognaive patients with functional neuroendocrine tumors. Novartis international package leaflet template, office97 version. Compatibility is denoted by an icon and simple description. Not compatible with tpn total parenteral nutrition. Octreotide 100 micrograms1ml solution for injection summary of. Medscape indicationspecific dosing for sandostatin, sandostatin lar octreotide. Epocrates delivers the most current safety, diagnostic and treatment information, right when you need it. It was first synthesized in 1979, by the chemist wilfried bauer. Octreotide brand name sandostatin, among others is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. On average, providers report saving 20 minutes or more a day with epocrates.
Following subq injection, immediaterelease formulation is rapidly and completely absorbed. Iv administration generally is reserved for emergency situations e. Patients controlled with octreotide im depot 20 to 30 mg. Octreotide acetate is stable in sterile isotonic saline solutions or sterile solutions of dextrose 5% in water for 24 hours. Closely follow mixing instructions included in the packaging. Iv injection suitable for shortacting formulations only in the treatment of oesophageal. Octreotide acetate reference guide for safe and effective use from the. Sandostatin octreotide acetate is not compatible in total parenteral nutrition tpn solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product. It was approved for use in the united states in 1988. Ns or d5w preferred diluent for acetaminophen overdose acyclovir. Subcutaneous injection is the usual route of administration of sandostatin for control of symptoms. Octreotide fda prescribing information, side effects and. Octreotide acetate is not compatible in total parenteral nutrition tpn solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.
1540 829 190 563 1372 193 762 82 942 174 1047 1352 734 28 685 48 677 18 29 613 1069 100 304 996 543 1258 1253 831 316 305 332 950 167 1441 1313 1026 75 1461